Valuation: Cadrenal Therapeutics, Inc.

Market Cap 5.85M 5.14M 4.78M 4.39M 8.24M 563M 8.37M 56.75M 22.17M 277M 21.97M 21.49M 958M P/E 2026 *
-0.51x
P/E 2027 * -0.68x
Enterprise Value 5.85M 5.14M 4.78M 4.39M 8.24M 563M 8.37M 56.75M 22.17M 277M 21.97M 21.49M 958M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.27%
Yield 2026 *
-
Yield 2027 * -
1 day+0.49%
1 week-5.56%
Current month-38.92%
1 month-31.54%
3 months-62.91%
6 months-71.90%
Current year-69.91%
1 week 1.86
Extreme 1.86
2.39
1 month 1.86
Extreme 1.86
3.89
Current year 1.86
Extreme 1.86
8.96
1 year 1.86
Extreme 1.86
14.64
3 years 1.86
Extreme 1.86
32.55
5 years 1.86
Extreme 1.86
101.25
10 years 1.86
Extreme 1.86
101.25
Manager TitleAgeSince
Chief Executive Officer 61 2022-01-24
Director of Finance/CFO 61 2026-06-24
Chief Operating Officer 58 2024-02-05
Director TitleAgeSince
Director/Board Member 76 2023-01-18
Director/Board Member 78 2023-01-18
Chairman 61 2022-01-24
Date Insider Type Main position Quantity % Market Cap.
6/29/26 Sell

Chief Executive Officer

-7,400 0.2580%
6/26/26 Sell

Chief Executive Officer

-9,029 0.3148%
6/23/26 Sell

Chief Executive Officer

-2,277 0.0794%
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%-5.56%-82.12%-87.15% 5.85M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -0.89%+0.59%+28.34%+145.14% 24.01B
Weighted average by Cap. -0.87%+2.10%+41.17%+135.68%

Financials

2026 *2027 *
Net sales - -
Net income -15.9M -13.96M -12.99M -11.92M -22.39M -1.53B -22.74M -154M -60.25M -753M -59.69M -58.4M -2.6B -20.5M -18.01M -16.74M -15.37M -28.87M -1.97B -29.31M -199M -77.68M -971M -76.96M -75.3M -3.36B
Net Debt - -
Logo Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
Employees
5
Date Price Change Volume
26-07-24 US$2.040 +0.49% 80,260
26-07-23 US$2.030 -3.33% 59,700
26-07-22 US$2.100 -3.23% 39,368
26-07-21 US$2.170 +3.83% 168,423
26-07-20 US$2.090 -3.24% 30,805
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.040USD
Average target price
16.67USD
Spread / Average Target
+716.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CVKD Stock